Prof Wee Loon Ong is a Radiation Oncologist, subspecialising in prostate cancer care. He is an Adjunct Clinical Professor at Monash University School of Translational Medicine.

He graduated from Monash University (2010), and completed an MPhil in Epidemiology from the University of Cambridge (2013), graduating first in class with the GSK prize. He undertook RANZCR Radiation Oncology specialty training (2016-2021) within the Victorian Training Network, and trained in Peter MacCallum Cancer Centre, Austin Health Olivia Newton-John Cancer Centre, and Ballarat Health. During that time, he concurrently pursued a Doctor of Medicine (MD) research degree through the University of Cambridge as part of the RANZCR Clinician-Scientist Training Pathway. He undertook further radiation oncology fellowship training in prostate cancer at the Alfred Health, Monash University (2021), and the Sunnybrook Odette Cancer Centre, University of Toronto (2022-2023).

He is actively involved in RANZCR, as a current member of the Radiation Oncology Research Committee (RORC) and executive committee member of the Faculty of Radiation Oncology Genitourinary Group (FROGG). He was previous Chair of the Radiation Oncology Trainee Committee (ROTC), and was trainee representative on the Faculty Council, and Quality Improvement Committee (QIC). He is the Convenor of the annual RANZCR Trainee SMART (Statistical Methods, Evidence Appraisal, and Research for Trainees) Workshop (2023 – present), and the Radiation Oncology Convenor of the 2025 RANZCR Annual Scientific Meeting. He is the current Chair of the Trans-Tasman Radiation Oncology Group (TROG) Genitourinary Working Party. He was the Academic Lead of PCOR-ANZ in 2024, and is currently the Deputy Chair of the PCOR-Vic Steering Committee and member of the PCOR-ANZ Advisory Committee. He is a member of American Society of Clinical Oncology (ASCO), American Society of Radiation Oncology (ASTRO), European Society for Radiotherapy and Oncology (ESTRO) Australian and New Zealand Urogenital and Prostate Trial Groups (ANZUP).

His research interests are the design and conduct of clinical trials in prostate cancer, and health services research using population-based administrative dataset and clinical quality registry. He is PI for multiple phase 2 prostate SABR trials at Alfred Health, and actively engages with international cooperative trial groups to bring international phase 3 trial on prostate radiation therapy into Australia. As an early-career clinician researcher, he has published widely, relative to opportunity and stage of career, with more than 80 publications to date, and in high impact journals such as JAMA, Journal of Clinical Oncology, JAMA Oncology, and European Urology. He has received multiple competitive grants and research awards, including the Victoria Veski Fellowship, ASCO Merit Awards, RANZCR Bourne and Langlands Prize, RANZCR Withers and Peters Scholarship, RANZCR FROGG Prize, RANZCR Quality Improvement Prize, RANZCR Wiley Exhibit Prize, RANZCR Medial Wealth Advisory Rural and Regional Award, and TROG Secondary Data Analysis Award. He is the Associate Editor of the Journal of Medical Imaging and Radiation Oncology (JMIRO), and is also regular peer reviewer for several other oncology journals.

He is highly-trained in all aspects of radiation therapy for prostate cancer, including stereotactic ablative body radiotherapy (SABR), low dose-rate brachytherapy (LDR-BT), and high dose-rate brachytherapy (HDR-BT). He has led the set-up of Prostate SABR programs across multiple centres in Victoria. He sees and treats patients at the Alfred Health, Latrobe Regional Health (Gippsland Radiation Oncology), and Barwon Health (Andrew Love Cancer Centre).